Roivant Sciences Ltd
ROIV19.870USD
+0.270+1.38%
收盤 11/04, 16:00（美東）報價延遲15分鐘
13.56B總市值
虧損本益比TTM
關於 Roivant Sciences Ltd 公司
Roivant Sciences Ltd. 是一家生物製藥公司，致力於通過加速重要藥物的開發和商業化來改善患者的生活。該公司的產品線包括免疫學、腫瘤學、血液學和皮膚病學等各個治療領域的候選產品。其產品線包括 IMVT-1402 和 batoclimab，它們是針對 FcRn 的完全人源單克隆抗體，正在開發用於多種 IgG 介導的自身免疫適應症；brepocitinib，一種 TYK2 和 JAK1 的小分子抑制劑，正在開發用於治療皮肌炎和非感染性葡萄膜炎；mosliciguat，一種吸入性可溶性 sGC 激活劑，正在開發用於治療與間質性肺病相關的肺動脈高壓，此外還有其他臨牀階段的分子；和 namilumab 是一種完全人源單克隆抗體，針對粒細胞-巨噬細胞集落刺激因子，一種與結節病等炎症性疾病有關的炎症細胞因子。
Roivant Sciences Ltd簡介
公司代碼ROIV
公司名稱Roivant Sciences Ltd
上市日期Dec 03, 2020
CEODr. Eric Venker, M.D.
員工數量750
證券類型Ordinary Share
年結日Dec 03
公司地址7Th Floor, 50 Broadway
城市LONDON
上市交易所NASDAQ Global Select Consolidated
國家United Kingdom
郵編SW1H 0DB
電話4412955950
網址http://roivant.com/
公司代碼ROIV
上市日期Dec 03, 2020
CEODr. Eric Venker, M.D.
Roivant Sciences Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.76%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.35M
--
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
187.68K
-2.33%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
--
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
99.80K
+1.24%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.14K
+0.69%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
+4.20%
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
40.50K
+2.68%
Mr. Daniel Gold
Mr. Daniel Gold
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.76%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.35M
--
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
187.68K
-2.33%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
--
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
99.80K
+1.24%
收入明細
FY2025Q1
業務USD
名稱
營收
佔比
VTAMA
55.13M
0.00%
地區USD
名稱
營收
佔比
United States
55.13M
0.00%
業務
地區
業務USD
名稱
營收
佔比
VTAMA
55.13M
0.00%
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Dexcel Pharma Technologies, Ltd.
15.06%
SB Investment Advisers (UK) Limited
8.78%
Fidelity Management & Research Company LLC
8.13%
Ramaswamy (Vivek)
7.16%
The Vanguard Group, Inc.
5.75%
其他
55.12%
持股股東
持股股東
佔比
Dexcel Pharma Technologies, Ltd.
15.06%
SB Investment Advisers (UK) Limited
8.78%
Fidelity Management & Research Company LLC
8.13%
Ramaswamy (Vivek)
7.16%
The Vanguard Group, Inc.
5.75%
其他
55.12%
股東類型
持股股東
佔比
Investment Advisor
26.27%
Investment Advisor/Hedge Fund
19.95%
Hedge Fund
15.83%
Corporation
15.06%
Private Equity
11.50%
Individual Investor
11.07%
Research Firm
2.05%
Pension Fund
0.50%
Venture Capital
0.45%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
685
526.71M
77.13%
-106.87M
2025Q2
673
776.63M
112.42%
-147.35M
2025Q1
676
776.88M
113.63%
-136.03M
2024Q4
645
780.70M
109.07%
-147.12M
2024Q3
601
789.51M
107.30%
-83.47M
2024Q2
564
721.13M
95.89%
-110.95M
2024Q1
518
776.24M
96.43%
-47.46M
2023Q4
449
787.20M
97.95%
-13.44M
2023Q3
421
794.31M
100.15%
+12.61M
2023Q2
394
761.99M
100.91%
+10.72M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Dexcel Pharma Technologies, Ltd.
102.85M
15.06%
--
--
Jul 01, 2025
SB Investment Advisers (UK) Limited
59.95M
8.78%
-1.90M
-3.07%
Jun 30, 2025
Fidelity Management & Research Company LLC
55.50M
8.13%
+3.83M
+7.41%
Jun 30, 2025
Ramaswamy (Vivek)
48.92M
7.16%
-1.78M
-3.50%
Sep 05, 2025
The Vanguard Group, Inc.
39.25M
5.75%
-1.44M
-3.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
35.53M
5.2%
-1.48M
-4.00%
Jun 30, 2025
Viking Global Investors LP
34.24M
5.01%
-11.78M
-25.59%
Jun 30, 2025
Morgan Stanley Investment Management Inc. (US)
33.37M
4.89%
+2.37M
+7.64%
Jun 30, 2025
QVT Financial LP
29.38M
4.3%
-36.41M
-55.34%
Jun 30, 2025
Rubric Capital Management LP
20.37M
2.98%
+2.60M
+14.65%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
Invesco S&P MidCap 400 Pure Growth ETF
2.77%
Virtus LifeSci Biotech Products ETF
2.2%
SPDR S&P Biotech ETF
1.82%
WisdomTree US Value Fund
1.3%
Goldman Sachs Future Health Care Equity ETF
1.25%
ProShares Ultra Nasdaq Biotechnology
1.07%
WisdomTree BioRevolution Fund
1.06%
Invesco Nasdaq Biotechnology ETF
1.04%
Direxion Daily S&P Biotech Bull 3X Shares
1.04%
WisdomTree US MidCap Fund
0.96%
查看更多
Invesco S&P MidCap 400 Pure Growth ETF
佔比2.77%
Virtus LifeSci Biotech Products ETF
佔比2.2%
SPDR S&P Biotech ETF
佔比1.82%
WisdomTree US Value Fund
佔比1.3%
Goldman Sachs Future Health Care Equity ETF
佔比1.25%
ProShares Ultra Nasdaq Biotechnology
佔比1.07%
WisdomTree BioRevolution Fund
佔比1.06%
Invesco Nasdaq Biotechnology ETF
佔比1.04%
Direxion Daily S&P Biotech Bull 3X Shares
佔比1.04%
WisdomTree US MidCap Fund
佔比0.96%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
